MX2010012438A - Formas de dosis de administracion oral que comprenden angiogenina y sus usos. - Google Patents

Formas de dosis de administracion oral que comprenden angiogenina y sus usos.

Info

Publication number
MX2010012438A
MX2010012438A MX2010012438A MX2010012438A MX2010012438A MX 2010012438 A MX2010012438 A MX 2010012438A MX 2010012438 A MX2010012438 A MX 2010012438A MX 2010012438 A MX2010012438 A MX 2010012438A MX 2010012438 A MX2010012438 A MX 2010012438A
Authority
MX
Mexico
Prior art keywords
angiogenin
milk
follistatin
dystrophy
muscle
Prior art date
Application number
MX2010012438A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Mcdonagh
Benjamin Cocks
Peter Hobman
Angus Tester
Original Assignee
Agriculture Victoria Serv Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008902371A external-priority patent/AU2008902371A0/en
Application filed by Agriculture Victoria Serv Pty filed Critical Agriculture Victoria Serv Pty
Publication of MX2010012438A publication Critical patent/MX2010012438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010012438A 2008-05-14 2009-05-14 Formas de dosis de administracion oral que comprenden angiogenina y sus usos. MX2010012438A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008902371A AU2008902371A0 (en) 2008-05-14 Oral preparation
PCT/AU2009/000602 WO2009137879A1 (en) 2008-05-14 2009-05-14 Orally administrable dosage forms comprising angiogenin and uses thereof

Publications (1)

Publication Number Publication Date
MX2010012438A true MX2010012438A (es) 2011-06-20

Family

ID=41318285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012438A MX2010012438A (es) 2008-05-14 2009-05-14 Formas de dosis de administracion oral que comprenden angiogenina y sus usos.

Country Status (14)

Country Link
US (1) US20110262422A1 (enExample)
EP (1) EP2307044A4 (enExample)
JP (1) JP2011519960A (enExample)
KR (1) KR20110033122A (enExample)
CN (1) CN102099050A (enExample)
AU (1) AU2009246052A1 (enExample)
BR (1) BRPI0911958A2 (enExample)
CA (1) CA2724048A1 (enExample)
IL (1) IL209284A0 (enExample)
MX (1) MX2010012438A (enExample)
NZ (1) NZ589306A (enExample)
RU (1) RU2010150934A (enExample)
WO (1) WO2009137879A1 (enExample)
ZA (1) ZA201009004B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101760758B1 (ko) * 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용
CA2818467A1 (en) * 2009-11-18 2011-05-26 Murray Goulburn Co-Operative Co. Limited Recombinant microorganisms
US20120328591A1 (en) * 2009-11-18 2012-12-27 Agriculture Victoria Services Pty Ltd Methods for improving oral delivery
WO2011060489A1 (en) * 2009-11-18 2011-05-26 Murray Goulburn Co-Operative Co. Limited Transgenic non-human animals
WO2011113100A1 (en) * 2010-03-17 2011-09-22 Murray Goulburn Co-Operative Co. Limited Method of treating a bone disorder
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014020676A1 (ja) * 2012-07-31 2014-02-06 雪印メグミルク株式会社 新規タンパク質素材
JP6140162B2 (ja) * 2012-07-31 2017-05-31 雪印メグミルク株式会社 骨強化用粉乳組成物及びその製造方法
AU2012386764B2 (en) * 2012-07-31 2016-05-05 Megmilk Snow Brand Co., Ltd. Powdered milk product, and method for producing same
MX2015001340A (es) * 2012-07-31 2015-09-04 Megmilk Snow Brand Co Ltd Producto novedoso de leche fermentada y metodo para preparar el mismo.
KR101996117B1 (ko) * 2012-07-31 2019-07-03 유키지루시 메그밀크 가부시키가이샤 음료 및 그 제조 방법
AU2012386761B2 (en) 2012-07-31 2016-05-05 Megmilk Snow Brand Co., Ltd. Beverage, and method for producing same
KR20150036687A (ko) * 2012-07-31 2015-04-07 유키지루시 메그밀크 가부시키가이샤 치즈류 및 그 제조 방법
AU2012386763B2 (en) 2012-07-31 2016-05-05 Megmilk Snow Brand Co., Ltd. Fermented milk product, and method for producing same
AU2012386758C1 (en) * 2012-07-31 2017-03-30 Megmilk Snow Brand Co., Ltd. Novel protein material
JP2016152809A (ja) * 2016-04-05 2016-08-25 雪印メグミルク株式会社 飲料及びその製造方法
JP6562956B2 (ja) * 2017-02-28 2019-08-21 雪印メグミルク株式会社 飲料及びその製造方法
JP6357266B2 (ja) * 2017-06-07 2018-07-11 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材
JP6357265B2 (ja) * 2017-06-07 2018-07-11 雪印メグミルク株式会社 骨疾患の予防又は治療用タンパク質素材

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2947657B2 (ja) * 1991-02-27 1999-09-13 森永乳業株式会社 神経成長因子産生促進剤
JP3929088B2 (ja) * 1996-06-20 2007-06-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
JPH10139682A (ja) * 1996-11-14 1998-05-26 Mitsubishi Chem Corp 骨吸収促進剤
CN1761463A (zh) * 2003-03-17 2006-04-19 日本烟草产业株式会社 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法
JP4698935B2 (ja) * 2003-05-07 2011-06-08 雪印乳業株式会社 皮膚コラーゲン産生促進剤
WO2004106491A2 (en) * 2003-05-22 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Angiogenin-based hiv-1 therapies
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
WO2007023479A2 (en) * 2005-08-23 2007-03-01 Royal College Of Surgeons In Ireland Treatment of central nervous system injury
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20070275036A1 (en) * 2006-05-18 2007-11-29 Celldyne Biopharma, Llc Avian follistatin product
US8551547B2 (en) * 2006-11-10 2013-10-08 Murray Goulburn Co-Operative Co., Limited Process for the preparation of angiogenin
KR101760758B1 (ko) * 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용

Also Published As

Publication number Publication date
CA2724048A1 (en) 2009-11-19
RU2010150934A (ru) 2012-06-20
EP2307044A4 (en) 2011-10-05
ZA201009004B (en) 2012-05-30
EP2307044A1 (en) 2011-04-13
JP2011519960A (ja) 2011-07-14
US20110262422A1 (en) 2011-10-27
WO2009137879A1 (en) 2009-11-19
BRPI0911958A2 (pt) 2015-10-13
NZ589306A (en) 2012-11-30
IL209284A0 (en) 2011-01-31
CN102099050A (zh) 2011-06-15
KR20110033122A (ko) 2011-03-30
AU2009246052A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
MX2010012438A (es) Formas de dosis de administracion oral que comprenden angiogenina y sus usos.
KR101760758B1 (ko) 질병 및 장애를 치료하기 위한 안지오게닌 또는 안지오게닌 아고니스트의 이용
EP2059260B1 (en) Pharmaceutical compositions comprising hGH for oral delivery
CN113248628B (zh) 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用
ES2887086T3 (es) Procedimiento para producir yema de huevo con alto contenido de af-16
EP3714885B1 (en) Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp)
ES2755177T3 (es) Composición que comprende la proteína HIP/PAP o uno de sus derivados para el tratamiento de la resistencia a la insulina
KR102239074B1 (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물
EP4208160A1 (en) Ionic liquid formulations for treating diabetes
CN116635023A (zh) 用于治疗糖尿病的离子液体制剂
US20100267630A1 (en) Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases
WO2025120002A1 (en) Petrelintide for reducing weight whilst preserving lean mass
JP2005232085A (ja) 活性酸素低減剤
WO2025120001A1 (en) Amylin analogues for reducing consumption of high-fat food
WO2022191184A1 (ja) グレリン受容体感受性増強剤、グレリン受容体感受性増強用組成物及びグレリン受容体の活性化方法
HK40037664A (en) Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp)
WO1999049727A1 (en) Antimicrobial protein compounds as novel oral hyperthermic agents for control of body weight and hypertension
JP2011201842A (ja) 腸由来細胞の増殖促進剤
ITMI20101181A1 (it) Composizioni perla riduzione del peso corporeo e della glicemia post prandiale

Legal Events

Date Code Title Description
FA Abandonment or withdrawal